

# Role of TGF beta-1 in regulating pancreatic neuroendocrine tumor cell viability


Simona Falletta<sup>1</sup>, Teresa Gagliano<sup>1</sup>, Erica Gentilin<sup>1</sup>, Carmelina Di Pasquale<sup>1</sup>, Katuscia Benfimi<sup>1</sup>, Vanessa Polenta<sup>2</sup>, Massimo Falconi<sup>2</sup>, Stefano Partelli<sup>2</sup>, Ettore degli Uberti<sup>1</sup>, Maria Chiara Zatelli<sup>1</sup>

<sup>1</sup> Department of Medical Science, Section of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy

<sup>2</sup> Pancreatic Surgery Unit, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy


## BACKGROUND

Pancreatic neuroendocrine tumors (pNETs) are neoplasms arising from neuroendocrine cells spread in the gastro-entero-pancreatic epithelium. The role of transforming growth factor beta-1 (TGF-β1) in NET biology is largely unknown. TGF-β1 signaling pathway is tumor suppressive in most non-transformed epithelial cell lines. In contrast, many human carcinomas are refractory to the growth-inhibitory effects of TGF-β1



## RESULTS


### CELL VIABILITY ASSAY




TGF-β1 reduced cell viability by 40% in “responder” pNETs.

In this group, TGF-β1 and Everolimus induced a significant decrease in cell viability by 65%, which was not observed under treatment with Everolimus alone

### RESPONDERS pNETs



### NON RESPONDERS pNETs



\*p<0.05 vs. control

TGF-β1 induced an increase by 37% in “non responder” pNETs and didn't influence the effect of Everolimus when used in combination.

## AIM


To investigate if TGF-β1 may modulate cell viability and apoptosis in NET of the pancreas and to understand whether TGF-β1 may influence the effects of therapeutic molecules currently used in the management of pNETs

## MATERIALS AND METHODS

20 primary cultures obtained from surgical samples of pNETs were treated with TGF-β1 and/or Everolimus, a mTOR inhibitor. Cell viability and caspase activity were evaluated




### CASPASE ACTIVITY ASSAY




TGF-β1 increased caspase activity by 53% in “responder” pNETs.

### RESPONDERS pNETs



\*\* p<0.01 vs. control

### NON RESPONDERS pNETs



\*\* p<0.01 vs. control

TGF-β1 decreased caspase activity by 30% in “non responder” pNETs.

## CONCLUSIONS

TGF-β1 reduces cell viability of a pNETs sub-group and may cooperate with Everolimus in inducing growth arrest. Further studies are necessary to understand TGF-β1 related functional context in pancreatic neuroendocrine tumors

